Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the Stifel 2024 Healthcare Conference in New York, scheduled for November 18-19, 2024. The company will present updates on its oncology and autoimmune disease programs, including recent data from Phase 1 clinical trials of CUE-101 and CUE-102 previously presented at SITC 2024.

CEO Daniel Passeri will lead the presentation on Tuesday, November 19, from 1:15-1:45 p.m. EST. The fireside chat will be accessible via webcast and archived for 30 days on the company's website.

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in a fireside chat at the Stifel 2024 Healthcare Conference being held in New York, NY, November 18-19, 2024.

During the fireside chat, Cue Biopharma will highlight current updates in its oncology and autoimmune disease programs. This includes discussing recent data highlights from its Phase 1 clinical programs, CUE-101 and CUE-102, presented at the recent Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024).

Presentation Details
Date and Time: Tuesday, November 19 from 1:15 p.m. EST – 1:45 p.m. EST
Webcast Link: https://wsw.com/webcast/stifel96/cue/1915582
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com

FAQ

When is Cue Biopharma presenting at the Stifel 2024 Healthcare Conference?

Cue Biopharma is presenting on Tuesday, November 19, 2024, from 1:15 p.m. to 1:45 p.m. EST at the Stifel 2024 Healthcare Conference in New York.

What clinical programs will Cue Biopharma discuss at the Stifel Conference?

Cue Biopharma will discuss updates from its Phase 1 clinical programs, CUE-101 and CUE-102, including recent data presented at SITC 2024.

How can investors access Cue Biopharma's Stifel Conference presentation?

Investors can access the presentation through a live webcast at wsw.com/webcast/stifel96/cue/1915582 or through the Events page on Cue Biopharma's website, where it will be archived for 30 days.